Weekly Digest – October 2024 Weekly Digest – October 2024 14 Oct 2024: SystImmune, Inc. announces FDA clearance of IND application for BL-M11D1 in relapsed/refractory Acute Myeloid Leukemia SystImmune, Inc. announced that the FDA has cleared its IND application for […]
Weekly Digest – October 2024 Weekly Digest – October 2024 16 Oct 2024: BlissBio receives IND approval from FDA for novel ADC BB-1712 BlissBio’s investigational new drug application for BB-1712, an antibody-drug conjugate targeting B7-H3, has been approved by the […]
Weekly Digest – October 2024 Weekly Digest – October 2024 14 Oct 2024: ENHERTU approved in China as first HER2 directed therapy for patients with HER2 mutant metastatic non-small cell lung cancer Daiichi Sankyo and AstraZeneca’s ENHERTU has received conditional […]
Weekly Digest – October 2024 Weekly Digest – October 2024 10 Oct 2024: Ono enters into license agreement for LCB97, an Antibody-Drug Conjugate, and research collaboration and license agreement to generate novel ADC candidates by leveraging ConjuAll ADC platform with […]
Weekly Digest – October 2024 Weekly Digest – October 2024 8 Oct 2024: MediLink Therapeutics and Amgen announce global clinical collaboration to evaluate combination therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) MediLink Therapeutics has partnered with Amgen to explore […]
Weekly Digest – October 2024 Weekly Digest – October 2024 8 Oct 2024: FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study Adcendo’s ADC candidate, ADCE-D01, received IND clearance from the US FDA and will enter […]
Weekly Digest – October 2024 Weekly Digest – October 2024 8 Oct 2024: CSPC Pharmaceutical announces CPO301 receives Fast Track Designation (FTD) from US FDA CSPC Pharmaceutical Group’s CPO301, a first-in-class ADC, received Fast Track Designation from the US FDA […]
Weekly Digest – October 2024 Weekly Digest – October 2024 10 Oct 2024: AstraZeneca’s dual-antibody ADC approved for two clinical trials in China AstraZeneca’s innovative drug AZD9592 has received implicit licensing for two clinical trials in China, targeting advanced solid […]
Weekly Digest – October 2024 Weekly Digest – October 2024 2 Oct 2024: Alentis Therapeutics secures FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting squamous cancers Alentis Therapeutics announced that the FDA has cleared the IND application for ALE.P02, […]
Weekly Digest – October 2024 Weekly Digest – October 2024 30 Sep 2024: Alphamab Oncology and CSPC enter licensing agreement for Anti-HER2 bispecific ADC JSKN003 Alphamab Oncology announced a licensing agreement for the anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with […]
